RxDoctor Payments Data

Kelly Bumpus

Podiatrist · Knoxville, TNNPI 1346531241

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,505 of the $7,589 with a category attached, or 72.5%. It is spread thinly across 42 manufacturers, the largest accounting for just 20.0%. Reporting peaked in 2019 at $2,642 and has fallen 61.6% since, to $1,014 in 2025.

$7,589in general payments, 2019–2025

Across 212 payments — averaging $35.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$2K
  • Alpha Orthopedic Systems$1K
  • Smith+Nephew$992
  • Arthrex$947
  • AbbVie$519
  • Progenacare Global, LLC$377
  • plus $2K from 36 others

What the payments were for

  • Travel & lodging$1,17215%
  • Food & beverage$5,50573%
  • Education$91212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,589 in reported general payments places this provider in the 80th percentile of 105 podiatrist providers in Tennessee.

See all podiatrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$211,958
Medicare patients
437
Services billed
2,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole16$19,801
Lidocaine-PrilocaineLidocaine/Prilocaine18$3,930
Ketoconazole31$695
Terbinafine Hcl49$476
Mupirocin43$334
Ciclopirox17$243
Doxycycline Hyclate34$239
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$211
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$173
Cephalexin36$167
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$165
Ciprofloxacin Hcl16$153
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$46
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$71$19,80116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 105 podiatrist providers in Tennessee.

Other podiatrist in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →